Vivi Paraskevi Riga

Consultant Ophthalmologist

Biography

Vivi Riga is a consultant ophthalmologist specialising in the fields of medical retina and uveitis. She was appointed in her current role in November 2024, having worked as a locum consultant in the same post at St Thomas’ Hospital for the past two years.

Vivi diagnoses and treats people with various retinal diseases, including:

  • age-related macular degeneration
  • diabetic eye disease
  • retinal vascular occlusions
  • central serous chorioretinopathy
  • other pachychoroid spectrum diseases
  • inherited retinal conditions

She also works for the medical eye unit, where she guides the diagnosis and management of a variety of complex autoimmune, inflammatory and infectious diseases and treats uveitis and scleritis patients with classic immunosuppression and biologic therapies.

Vivi delivers retinal and macular laser treatments and a variety of intraocular injections in addition to working closely with the multidisciplinary teams and other subspecialties in the management of complex cases.

She takes great interest in the teaching and training of the resident doctors, fellows, nurses and allied health professionals.

Vivi’s work is mostly concerned with improving clinical outcomes for her patients through personalised, responsive and participative care.

Education and training

  • Senior clinical fellowship in uveitis, cataract and medical retina, Moorfield’s Eye Hospital (2020-2022)
  • Senior clinical fellowship in medical retina and the medical eye unit, St Thomas’ Hospital (2018-2020)
  • Fellowship of the European Board of Ophthalmology (FEBO) (2018)
  • Ophthalmology training, 2nd Department of Ophthalmology, Aristotle University of Thessaloniki (2013-2017)
  • Doctor of Medicine (MD), Aristotle University of Thessaloniki, Greece (2009)

Research interests

Vivi is interested in clinical trials aiming to investigate novel treatments in retinal and autoimmune diseases.

She has previously worked in large, multicentre randomised controlled Phase 3 and Phase 4 trials in the use of intravitreal anti-VEGF injections for patients with age-related macular degeneration, retinal vascular occlusion and choroidal neovascularisation of various causes.

Last updated: January 2025

Is this page useful?